Full Title
A First-in-Human (FIH) Study of IDRX-42 in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)Purpose
In this study, researchers want to see how safe IDRX-42 is and how well it works to treat cancer. The people in this study have gastrointestinal stromal tumor (GIST) that keeps growing after treatment. In addition, their cancer has metastasized (spread) or is inoperable (cannot be taken out with surgery).
IDRX-42 blocks a range of proteins that fuel GIST growth. Other GIST treatments take aim at only a few proteins, and the cancer may become resistant to them. Researchers think IDRX-42 may work better because it blocks more proteins than any of the standard treatments alone. This may stop or slow cancer growth and prevent or delay treatment resistance. IDRX-42 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have metastatic or inoperable GIST that keeps growing even after treatment.
- Have recovered from the serious side effects of prior cancer therapies.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Ciara Kelly’s office at 646-888-4312.